CURRICULUM VITAE - 11/01/2017 NAME: James Francis Howard, Jr., M.D. OFFICE ADDRESS: Department of Neurology 2200 Physicians Office Bldg., CB#7025 170 Manning Drive The University of North Carolina School of Medicine Chapel Hill, NC 27599-7025 E-MAIL: [email protected] TELEPHONE: Home: on request Office: 919.966.8168 Admin: 919.966.9281 EMG Laboratory 984.974.1686 Facsimile: 919.966.2922 EDUCATION: • Research Associate in Neuromuscular Disease, University of Virginia School of Medicine, Charlottesville, Virginia, 1978 — 1979 • Resident, Neurology, University of Virginia Hospital, Charlottesville, Virginia, 1975 — 1978 • Intern, Internal Medicine, Albany Medical Center Hospital, Albany, New York, 1974 — 1975 • M.D., University of Vermont School of Medicine, Burlington, Vermont, 1974 • B.A. (Special Honors in Anatomy), University of Vermont, Burlington, Vermont, 1970 EMPLOYMENT HISTORY: • Professor of Neurology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; July 1, 1992 to present James F. Howard Distinguished Professor of Neuromuscular Disease, November, 2003 • Adjunct Professor of Allied Health Sciences, University of North Carolina School of Medicine, Chapel Hill, North Carolina; October 1, 2011 to present • Adjunct Professor of Clinical Sciences (Neurology), North Carolina State University College of Veterinary Medicine, Raleigh, North Carolina, January 1, 2005 to present • Associate Professor of Neurology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; July 1, 1985 through June 30, 1992 • Assistant Professor of Neurology and Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; July 1, 1979 through June 30, 1985 • Instructor in Neuromuscular Disease, University of Virginia School of Medicine, Charlottesville, Virginia; July 1, 1978 through June 30, 1979 Curriculum Vitae November 6, 2017 Howard, James F., Jr. Page 2 CERTIFICATION AND LICENSURE: • Diplomate, Professional Ski Instructors of America (formerly the United States Eastern Amateur Ski Association), 1969 (currently inactive) • Diplomate, National Board of Medical Examiners, 1975 • Diplomate, American Board of Psychiatry and Neurology, 1980 • Diplomate, American Board of Electrodiagnostic Medicine, 1989 (#0412) • Licensed M.D., Virginia (#0101030059) 1978; North Carolina (#23383) 1979 HOSPITAL APPOINTMENTS: • Attending Physician, University of North Carolina Hospitals, July 1979 to present PROFESSIONAL SOCIETIES: • American Academy of Neurology, 1975 to present Fellow, 1986 to present Active, 1979 — 1986 Junior, 1975 — 1979 • American Association of Neuromuscular & Electrodiagnostic Medicine (formerly the American Association of Electrodiagnostic Medicine and American Association of Electromyography and Electrodiagnosis), 1981 to present Active, 1981 — 1989 Fellow member by examination, 1989 to present Board of Directors, 2002 — 2005 • American Board of Electrodiagnostic Medicine Board of Directors, 2008 — present Examiner, 2002, 2003, 2009 Exam Supervisor, 2009, 2010, 2012 — 2014 • American Medical Association, 1979 to present • American Neurological Association, 1997 to present • International Brain Research Organization/World Federation of Neuroscientists, 1980 to present • Myasthenia Gravis Foundation of America Medical/Scientific Advisory Board, 1979 to present Chair, 2003 — 2005 Vice Chair, 2001 — 2003 Secretary, 1999 — 2001 • New York Academy of Sciences, 1980 to present • North Carolina Medical Society, 1979 to present Chair, Neurology Section, 1994 • North Carolina Neurological Society, 1979 to present President, 1994 Vice President, 1993 Board of Directors, 2000 — 2009 • Orange-Durham County Medical Society, 1979 to present • Society for Neurosciences, 1980 to present • Professional Ski Instructors of America, (formerly the United States Eastern Amateur Ski Association), member by examination, 1969 — 1980; currently inactive status Curriculum Vitae November 6, 2017 Howard, James F., Jr. Page 3 EDITORIAL BOARDS • Associate Editor (founding), Journal of Clinical Neuromuscular Disease, Lippincott, Williams & Wilkins, 1998 — 2006 • Member, Editorial Board, IgNews: Current Topics in Immunoglobulin Research and Therapy, American Red Cross, 2002 — 2004 GRANTS FUNDED (ACTIVE): • Principal Site Investigator: Safety and Efficacy Study of RA101495 in Subjects with Generalized Myasthenia Gravis. Ra Pharmaceuticals Inc. 2017 – 2019. • Site Investigator: A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy. Vertex Pharmaceuticals Inc. 2017 – 2019. • Global Lead Principal Investigator: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness. Argenx BVBA. 2017 – 2019. • Principal Site Investigator: Investigations into the role of autoantibodies to the LRP4 protein in patients with Myasthenia Gravis. NIH/Georgia Health Sciences University. 2016 – 2019 • Co-Investigator: Comp B-Surveillance and Research of Muscular Dystrophy and Neuromuscular Disorders. U01DD001116, Centers for Disease Control, and Prevention (CDC), National Center on Birth Defects and Developmental Disabilities (NCBDDD). Whitehead N (PI). 2014 – 2019. • Global Lead Principal Investigator: A randomized, double-blind, placebo-controlled, multi- center study to evaluate the safety and efficacy of eculizumab in subjects with refractory generalized myasthenia gravis (GMG), ECU-301, ECU-302, IND 101,219, EudraCT #2013- 003589-15. Alexion Pharmaceuticals, Inc. Howard JF (PI). 2014 – 2018. • Investigator: Autoimmune mechanisms in a novel Aire-deficient model of peripheral neuropathy. NIH/ Environmental Med, Asthma and Lung Biology, 1-R01-NS079683-01A1, Su, M (PI), 2013 — 2018. • Principal Site Investigator: Duchenne Muscular Dystrophy: Double-Blind Randomized Trial to find the optimum Steroid Regimen (FOR-DMD) NIH/NINDS U01-NS061799-01A2, Griggs B (PI), 2013 — 2021. • Co-Investigator: DP ARF Ultrasound for Monitoring Muscle Degeneration in Duchenne Muscular Dystrophy, NIH R01 NS074057-01A1, Gallippi C (PI), 2011 — 2017. GRANTS SUBMITTED (PENDING): • Principal Site Investigator: Characterization of T cell responses in inclusion body myositis. NIH Exploratory/Developmental Research Grant Program (Parent R21). Guptill, J (PI). GRANTS FUNDED (COMPLETED): • Principal Site Investigator: Exploratory Study of Immunological Profiles in Myasthenia Gravis Subjects that Receive Therapeutic Plasma Exchange. UCB Biosciences. Guptill, J (PI). 2014 — 2015. • Principal Site Investigator: BEL115123: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Belimumab in Patients with Myasthenia Gravis (MG). GlaxoSmithKline Pharmaceuticals, Inc., 2013 — 2015. • Principal Site Investigator: A phase II randomized, double-blinded, controlled trial of methotrexate versus placebo in Myasthenia Gravis patients who are considered steroid dependent. NIH/NINDS (University of Kansas), R01FD003538, Barohn R (PI), 2011 — 2014. Curriculum Vitae November 6, 2017 Howard, James F., Jr. Page 4 • Investigator: Safety and Feasibility of Transvenous Limb Perfusion with Normal Saline in Human Muscular Dystrophy, Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, NIH/NIAMS 1U54AR056953-01, Powers WJ (PI), 2008 — 2013. • Principal Site Investigator: A Phase II, Randomized, Three-Way Crossover, Placebo- Controlled, Pharmacodynamic Study of CK-2107357 in Patients with Generalized Myasthenia Gravis on Standard Therapy, Cytokinetics, Inc., CY 4023/ NINDS 1RC3NS070670-01; CFDA Number: 93.71, 2011 — 2013. • Co-Investigator: Automated Atlas-based Muscle MRI Quantification in Duchenne Muscular Dystrophy Patients, NC TraCS # 50KR71104, University of North Carolina, Fan Z (PI), 2011 — 2012. • Principal Site Investigator: A randomized, double-blind, placebo-controlled, cross-over, multi-center study of eculizumab in patients with generalized myasthenia gravis (GMG) who have moderate to severe weakness despite treatment with immunosuppressants. Alexion Pharmaceuticals, Inc., C08-001, 2008 — 2012. • Principal Site Investigator: Genome wide association study in Myasthenia Gravis. Myasthenia Gravis Foundation of America, 2010 — 2011. • Consultant: Pilot evaluation of the effects of substance P-saporin (SP-SAP) on chronic pain due to osteoarthritis in companion dogs. (PI: Olby, Natasha & Lascelles, Duncan), Novartis, 2010 — 2011. • Consultant: Development of a technique for measuring canine phrenic nerve conduction velocity. (PI: Olby, Natasha & Matthews, Kyle), NCSU, 2010 — 2011. • Investigator: Pudendal Nerve Function as a Predictor of Female Sexual Function with Sacral Neuromodulation. (PI: Parnell, B.) American Urogynecologic Society, 2010 — 2011. • Investigator: National Center for Canine Models of Duchene Muscular Dystrophy ARRA, NIH/NINDS 3-U24-NS059696-01A1S1, 2009 — 2011 • Sub-Investigator: The Natural History of Infantile Globoid Cell Leukodystrophy. Zymenex A/S, rhGALC-01, 2009 — 2011. • Sub-Investigator: The Natural History of Metachromatic Leukodystrophy. Zymenex A/S, 2008 — 2011. • Principal Investigator: Investigation of the ability of Otelixizumab to inhibit in vitro antigen- specific T cell responses from Myasthenia Gravis patients. GlaxoSmithKline Pharmaceuticals, Inc., MGO113510, 2010. • Consultant: Prednisone